Big data and biobanks support improved diagnosis and treatment for heart disease in diabetics
The prevalence of type 2 diabetes has reached a pandemic scale with patients at an elevated risk for developing cardiomyopathy, a heart muscle disease that makes it difficult for the heart to pump blood, and heart failure is a leading cause of death. While diabetic cardiomyopathy (DCM) has been recognised as a distinct clinical condition, it is not certain if DCM does in fact have different development and disease progression compared to conventional cardiomyopathy. The CARDIATEAM initiative intends to answer this question by comparing diabetes and heart failure patients and healthy controls. Finding biomarkers of DCM while simultaneously developing big-data processing techniques to identify risk groups based on phenotypic differences should foster early diagnosis and treatment for better outcomes.
Field of science
- /medical and health sciences/basic medicine/physiology/pathophysiology
- /medical and health sciences/clinical medicine/endocrinology/diabetes
Call for proposal
See other projects for this call
Funding SchemeIMI2-RIA - Research and Innovation action